Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab is
effective and safe in the treatment of patients with relapsed/refractory diffuse large B-cell
lymphoma (DLBCL).